| pubmed-article:20105224 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20105224 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
| pubmed-article:20105224 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:20105224 | lifeskim:mentions | umls-concept:C0242957 | lld:lifeskim |
| pubmed-article:20105224 | lifeskim:mentions | umls-concept:C0449438 | lld:lifeskim |
| pubmed-article:20105224 | lifeskim:mentions | umls-concept:C1441616 | lld:lifeskim |
| pubmed-article:20105224 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:20105224 | lifeskim:mentions | umls-concept:C1522609 | lld:lifeskim |
| pubmed-article:20105224 | lifeskim:mentions | umls-concept:C1554112 | lld:lifeskim |
| pubmed-article:20105224 | lifeskim:mentions | umls-concept:C0205473 | lld:lifeskim |
| pubmed-article:20105224 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:20105224 | pubmed:dateCreated | 2010-11-2 | lld:pubmed |
| pubmed-article:20105224 | pubmed:abstractText | The serodiagnostics of extracellular domain (ECD) HER-2/neu has turned into an evidenced-based tumour marker for HER-2/neu-positive breast cancer patients. This study investigated the clinical relevance of immunohistochemical and serum HER-2/neu in 44 patients with advanced ovarian cancer. The Hercept-Test® from DAKO Diagnostics was used to analyse immunohistochemical HER-2/neu expression. The HER-2/neu ECD in serum was determined quantitatively by Bayer Immuno 1™ Immunoanalyser. The HER-2/neu serum values were correlated to the clinical course of disease and to established prognostic factors, i.e. progression-free and overall survival. Some 23% of patients (n = 11) expressed HER-2/neu serum levels higher than 15 ng/mL, whereas only 7.7% (n = 2) of the patients examined by immunohistochemistry showed a HER-2/neu overexpression of the tissue. None of them revealed an overexpression of HER-2/neu ECD by serodiagnostics. HER-2/neu overexpression did not correlate significantly to any of the analysed prognostic factors. According to progression-free and overall survival, there was no significant difference between serologically HER-2/neu-positive or negative patients. For ovarian cancer patients, neither high HER-2/neu serum levels, nor immunohistochemically determined HER-2/neu positivity, appear to predict the course of disease. This study shows a lack of association between the immunohistochemical HER-2/neu status and the serum level of solute extracelluar HER-2/neu domain. | lld:pubmed |
| pubmed-article:20105224 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20105224 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20105224 | pubmed:citationSubset | N | lld:pubmed |
| pubmed-article:20105224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20105224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20105224 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20105224 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:20105224 | pubmed:issn | 1365-2354 | lld:pubmed |
| pubmed-article:20105224 | pubmed:author | pubmed-author:BeckerMM | lld:pubmed |
| pubmed-article:20105224 | pubmed:author | pubmed-author:ThomasAA | lld:pubmed |
| pubmed-article:20105224 | pubmed:author | pubmed-author:NeumannRR | lld:pubmed |
| pubmed-article:20105224 | pubmed:author | pubmed-author:SchöndorfTT | lld:pubmed |
| pubmed-article:20105224 | pubmed:author | pubmed-author:OrtmannMM | lld:pubmed |
| pubmed-article:20105224 | pubmed:author | pubmed-author:MallmannPP | lld:pubmed |
| pubmed-article:20105224 | pubmed:author | pubmed-author:SachseKK | lld:pubmed |
| pubmed-article:20105224 | pubmed:author | pubmed-author:HoopmannMM | lld:pubmed |
| pubmed-article:20105224 | pubmed:author | pubmed-author:ValterM MMM | lld:pubmed |
| pubmed-article:20105224 | pubmed:author | pubmed-author:GöhringU-JUJ | lld:pubmed |
| pubmed-article:20105224 | pubmed:copyrightInfo | © 2010 Blackwell Publishing Ltd. | lld:pubmed |
| pubmed-article:20105224 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20105224 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:20105224 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20105224 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20105224 | pubmed:pagination | 809-15 | lld:pubmed |
| pubmed-article:20105224 | pubmed:meshHeading | pubmed-meshheading:20105224... | lld:pubmed |
| pubmed-article:20105224 | pubmed:meshHeading | pubmed-meshheading:20105224... | lld:pubmed |
| pubmed-article:20105224 | pubmed:meshHeading | pubmed-meshheading:20105224... | lld:pubmed |
| pubmed-article:20105224 | pubmed:meshHeading | pubmed-meshheading:20105224... | lld:pubmed |
| pubmed-article:20105224 | pubmed:meshHeading | pubmed-meshheading:20105224... | lld:pubmed |
| pubmed-article:20105224 | pubmed:meshHeading | pubmed-meshheading:20105224... | lld:pubmed |
| pubmed-article:20105224 | pubmed:meshHeading | pubmed-meshheading:20105224... | lld:pubmed |
| pubmed-article:20105224 | pubmed:meshHeading | pubmed-meshheading:20105224... | lld:pubmed |
| pubmed-article:20105224 | pubmed:meshHeading | pubmed-meshheading:20105224... | lld:pubmed |
| pubmed-article:20105224 | pubmed:meshHeading | pubmed-meshheading:20105224... | lld:pubmed |
| pubmed-article:20105224 | pubmed:meshHeading | pubmed-meshheading:20105224... | lld:pubmed |
| pubmed-article:20105224 | pubmed:meshHeading | pubmed-meshheading:20105224... | lld:pubmed |
| pubmed-article:20105224 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20105224 | pubmed:articleTitle | Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients. | lld:pubmed |
| pubmed-article:20105224 | pubmed:affiliation | Department of Obstetrics and Gynaecology, University Hospital of Cologne, Cologne, Germany. | lld:pubmed |
| pubmed-article:20105224 | pubmed:publicationType | Journal Article | lld:pubmed |
